CK Life Sciences Int'l., (Holdings) Inc. announced that its subsidiary Sequencio Therapeutics Company Limited has had two abstracts selected for presentation at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place 4-8 November 2026 in Phoenix, Arizona. The presentations will detail preclinical findings from two lead cancer vaccine programmes, offering the international immuno-oncology community a first look at data generated under Sequencio's Prime–Infiltrate–Ignite–Translate (PINT) translational research framework. The announcement was distributed via Media OutReach Newswire.
The significance of the data lies in the two programmes' complementary strategies for overcoming central obstacles in cancer immunotherapy: enabling the immune system to recognise and attack cancer cells, and countering the mechanisms tumours use to evade immune responses. The first programme, CKLS118, pairs a TROP2 circular RNA vaccine with checkpoint inhibition. In preclinical models, the combination increased activated IFN-γ-positive CD4+ and CD8α+ T-cell subsets within tumours, indicating greater local immune activation. In the 4T1-hTROP2 model, tumour growth inhibition reached 74.7% and 88.9% when the vaccine was combined with 0.3 and 1.0 mg/kg anti-PD-1, respectively, compared with 28.9% and 68.6% with anti-PD-1 alone. These results support further development of CKLS118 in combination with checkpoint inhibition and the evaluation of a potential dose-sparing strategy.
The second programme, CKLS202, is a dual-antigen vaccine co-targeting human PD-L1 and PRAME. It is designed to combine tumour-antigen targeting with PD-L1-directed immune modulation in a single vaccine. In humanised models, vaccination induced robust PRAME-specific T-cell responses, anti-human PD-L1 antibody titres above 1:16,000 and functional hPD-1/hPD-L1 blockade. In the efficacy model, vaccination achieved 65% tumour growth inhibition and was associated with increased tumour-infiltrating CD4+ cells, more than twofold increases in interferon-γ and granzyme B, and a more than fivefold reduction in the M2 macrophage marker CD163, consistent with a shift toward a more immune-active tumour environment. Vaccinated tumour-free mice were also protected against tumour rechallenge, supporting durable antigen-specific immunity.
Dr Melvin Toh, Vice President and Chief Scientific Officer of CK Life Sciences, said the two posters provide an important opportunity to share new data with the international immuno-oncology community. He noted that the findings provide preclinical evidence supporting the intended mechanisms of action of the cancer vaccines and demonstrate how the programmes may generate and sustain anti-tumour immune responses. Dr Toh added that the findings may also help inform future clinical development in peri-operative settings, where lower tumour burden may give vaccine-induced immunity a greater opportunity to control residual disease.
For CK Life Sciences, the SITC selection represents external validation of its translational research approach and positions Sequencio's candidates for advancement toward human clinical trials. The use of humanised preclinical models contributes to the PINT framework's Translate element by helping researchers assess how findings may be relevant to humans. Sequencio's stated vision is to shift cancer treatment from transient tumour reduction toward sustained, immune-controlled remission.


